Advertisement

CNS Drugs

, Volume 1, Issue 3, pp 180–192 | Cite as

Childhood Epilepsy

Current Therapeutic Recommendations
  • Jamie T. Gilman
  • Michael Duchowny
Practical Therapeutics

Summary

The pharmacotherapy of epilepsy in children must account for a number of specific issues. The nature of epileptic disorders found in children differs from that in adults. For example, epilepsies of childhood are more likely to be developmentally or genetically based than those found in adults. Children also differ from adults in indications for antiepileptic drugs. Indeed, some types of childhood epilepsy do not require specific pharmacological treatment since prognosis is often excellent without therapy. This is especially true for children who are neurologically nonnal and those with benign epilepsy syndromes that have a characteristic electroclinical presentation, such as febrile seizures. In contrast, children with evidence of brain damage or those with serious epilepsy syndromes must be treated promptly.

Once it has been decided that treatment is necessary, the choice of treatment should be based on a comparison of efficacy and tolerability of individual antiepileptic agents. The spectrum of toxicity is often different in younger patients from that in adults, and adverse effects that are acceptable in adults may be cause for discontinuation of therapy in children. Intellectual, cognitive and behavioural toxicity are particularly unacceptable.

Establishing sustained therapeutic serum concentrations in children also requires specific attention. Rapid gastrointestinal transit times and interactions with milk and infant formulas may pose special management problems. Toxic metabolites of antiepileptic drugs are frequently produced in children. This can lead to drug hypersensitivity and other possible conditions, such as valproic acid (sodium valproate)-induced hepatotoxicity.

Unless specific paediatric data are obtained, recommendations for the treatment of epilepsies in children will continue to be based on studies in adults and on anecdotal observations. Given the high prevalence and significant morbidity of childhood epilepsies, further studies of treatments are urgently needed.

Keywords

Carbamazepine Valproic Acid Lamotrigine Vigabatrin Febrile Seizure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hauser WA, Hesdorffer DC, editors. Incidence and prevalence. In: Epilepsy: frequency, causes and consequences. New York, New York: Demos Publications, 1990: 1–51Google Scholar
  2. 2.
    Gomez MR, Klass DW. Epilepsies of infancy and childhood. Ann Neurol 1983; 13: 113–24PubMedCrossRefGoogle Scholar
  3. 3.
    Aicardi J. Epilepsy and the developing brain. Brain Dysfunct 1992; 5: 200–10Google Scholar
  4. 4.
    Wyllie E. Seizure management in children. Selecting the nontreatment option. Int Pediatr 1993; 8: 280–4Google Scholar
  5. 5.
    Nelson KB, Ellenberg JH. Prognosis in children with febrile seizures. Pediatrics 1978; 61: 720–7PubMedGoogle Scholar
  6. 6.
    Berg AT, Shinnar S, Hauser WA, et al. Predictions of recurrent febrile seizures: a metaanalytic review. J Pediatr 1990; 116: 329–37PubMedCrossRefGoogle Scholar
  7. 7.
    Hauser WA, Kurland LT. The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia 1975; 16: 1–66PubMedCrossRefGoogle Scholar
  8. 8.
    Shinnar S, Berg D, Moshe SL, et al. The risk of seizure recurrence following a first unprovoked seizure in childhood: a prospective study. Pediatrics 1990; 85: 1076–85PubMedGoogle Scholar
  9. 9.
    Hauser WA, Rich SS, Annegers IF, et al. Seizure recurrence after a first unprovoked seizure: an extended follow-up. Neurology 1990; 40: 1163–70PubMedCrossRefGoogle Scholar
  10. 10.
    Sassower K, Duchowny M. Psychogenic seizures and nonepileptic phenomena in children. In: Devinsky O, Theodore WH, editors. Epilepsy and behavior. New York: Wiley-Liss Inc., 1991: 223–35Google Scholar
  11. 11.
    Duchowny MS, Resnick TJ, Deray MJ, et al. Video EEG diagnosis of repetitive behavior in early childhood and its relationship to seizures. Pediatr Neurol 1988; 4: 162–4PubMedCrossRefGoogle Scholar
  12. 12.
    Delgado-Escueta AV, Treiman DM, Walsh GO. The treatable epilepsies. N Eng J Med 1983; 308: 1508–14CrossRefGoogle Scholar
  13. 13.
    Abramowicz M. Drugs for epilepsy. Med Lett Drugs Ther 1989; 31: 1–4Google Scholar
  14. 14.
    Rosenberg HC, Tietz EI, Chiu TH. Tolerance to anticonvulsant effects of diazepam, clonazepam and clobazam in amygdalakindled rats. Epilepsia 189: 30: 276–85Google Scholar
  15. 15.
    Scarpa P, Carassini B. Partial epilepsy in childhood. Clinical and EEG study of 261 cases. Epilepsia 1982; 23: 333–41PubMedCrossRefGoogle Scholar
  16. 16.
    Resnick TJ. Criteria for surgical evaluation in children with uncontrolled seizures. J Epilepsy 1990; 3 Suppl.: 35–40Google Scholar
  17. 17.
    Ramsay RE, Wilder BJ, Berger JR, et al. A double-blind study comparing carbamazepine with phenytoin as initial seizure therapy in adults. Neurology 1983; 33: 904–10PubMedCrossRefGoogle Scholar
  18. 18.
    Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313: 145–51PubMedCrossRefGoogle Scholar
  19. 19.
    Mattson RH, Cramer JA, Collins JF, et al. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992; 327: 765–71PubMedCrossRefGoogle Scholar
  20. 20.
    Herranz JL, Armijo JA, Arteaga R. Clinical side effects of phenobarbital, primidone, phenytoin, carbamazepine, and valproate during monotherapy in children. Epilepsia 1988; 29: 794–804PubMedCrossRefGoogle Scholar
  21. 21.
    Falconer MA, Davidson S. Coarse features in epilepsy as a consequence on anticonvulsant therapy. Report of cases in two pairs of identical twins. Lancet 1973; 2 (838): 112–4Google Scholar
  22. 22.
    Angelopoulos AP, Goaz pw. Incidence of diphenylhydantoin gingival hyperplasia. Oral Med Oral Pathol 1972; 34: 898–906CrossRefGoogle Scholar
  23. 23.
    Philstrom BL, Carlson JF, Smith QT, et al. Prevention of phenytoin associated gingival enlargement: a l5-month longitudinal study. J Periodontol 1980; 51: 311–7CrossRefGoogle Scholar
  24. 24.
    Marshall WR, Lattanzi DA, Weaver GS, et al. Laser excision of type III phenytoin-induced gingival hyperplasia. Special Care Dent 1987 Sept-Oct: 207–10Google Scholar
  25. 25.
    Carrel R, Ba TT, Chapman MK. Gingival aberrations in dilantin- treated guinea pigs. J Periodont 1983; 7: 229–40Google Scholar
  26. 26.
    Farwell JR, Lee YJ, Hirtz DG, et al. Phenobarbital for febrile seizures—effects on intelligence and on seizure recurrence. N Engl J Med 1990; 322: 364–9PubMedCrossRefGoogle Scholar
  27. 27.
    Trimble MR, Cull C. Children of school age: the influence of antiepileptic drugs on behavior and intellect. Epilepsia 1988; 29 Suppl. 3: S15–9CrossRefGoogle Scholar
  28. 28.
    Vining EPG, Mellits ED, Dorsen MM, et al. Psychologic and behavioral effects of antiepileptic drugs in children: a doubleblind comparison between phenobarbital and valproic acid. Pediatrics 1987; 80: 165–74PubMedGoogle Scholar
  29. 29.
    Gallassi R, Morreale A, Lorusso S, et al. Carbamazepine and phenytoin. Comparison of cognitive effects in epileptic patients during monotherapy and withdrawal. Arch Neurol 1988; 45: 892–4PubMedCrossRefGoogle Scholar
  30. 30.
    Coulter DL. Camitine, valproate, and toxicity. J Child Neurol 1991; 6: 7–14PubMedCrossRefGoogle Scholar
  31. 31.
    Vance CK, Vance WH, Winter SC, et al. Control of valproateinduced hepatotoxicity with camitine [abstract]. Ann Neurol 1989; 26: 456Google Scholar
  32. 32.
    Murphy Jv, Groover RV, Hodge C. Hepatotoxic effects in a child receiving valproate and camitine. J Pediatr 1993; 123: 318–20PubMedCrossRefGoogle Scholar
  33. 33.
    Driefuss FE, Langer DH, Moline KA, et al. Valproic acid hepatic fatalities. II. US experience since 1984. Neurology 1989; 39: 201–7CrossRefGoogle Scholar
  34. 34.
    Pellock JM, Willmore LJ. A rational guide to routine blood monitoring in patients receiving antiepileptic drugs. Neurology 1991; 41: 961–4PubMedCrossRefGoogle Scholar
  35. 35.
    Asconape JJ, Penry JK, Dreifuss FE, et al. Valproate-associated pancreatitis. Epilepsia 1993; 34: 177–83PubMedCrossRefGoogle Scholar
  36. 36.
    Schain RJ. Carbamazepine and cognitive functioning. In: Morselli PL, Pippenger CE, Penry JK, editors. Antiepileptic drug therapy in pediatrics. New York: Raven Press, 1983: 189–92Google Scholar
  37. 37.
    Schoeman JF, Elyas AA, Brett EM, et al. Correlation between plasma carbamazepine-lO,l1-epoxide concentration and drug side-effects in children with epilepsy. Dev Med Child Neur 1984; 26: 756–64CrossRefGoogle Scholar
  38. 38.
    Pellock JM. Carbamazepine side effects in children and adults. Epilepsia 1987; 28 Suppl. 3: S64–70CrossRefGoogle Scholar
  39. 39.
    Farrell K. Benzodiazepines in the treatment of children with epilepsy. Epilepsia 1986; 27 Suppl. 1: S45–51CrossRefGoogle Scholar
  40. 40.
    Snead OC, Benton JW, Myers GJ. ACTH and prednisone in childhood seizure disorders. Neurology 1983; 33: 966–70PubMedCrossRefGoogle Scholar
  41. 41.
    Pearl PL, Holmes GL. Epileptic syndromes and their prognosis. In: Roger J, Dravet C, Bureau M, et al., editors. Epileptic syndromes in infancy, childhood and adolescence. London: John Libbey & Co. Ltd, 1985: 8–25Google Scholar
  42. 42.
    Roger J, Dravet C, Bureau M, et al. editors. Epileptic syndromes in infancy, childhood and adolescence. London: John Libbey & Co. Ltd, 1985Google Scholar
  43. 43.
    Jeavons PM, Bower BD, Dimitrakoudi M. Long-term prognosis of 150 cases of “West syndrome”. Epilepsia 1973; 14: 153–64PubMedCrossRefGoogle Scholar
  44. 44.
    Hauser WA, Hesdorffer DC, editors. Seizures and the developmental disabilities. In: Epilepsy: frequency, causes and consequences. New York, New York: Demos Publications, 1990: 327–47Google Scholar
  45. 45.
    Dulac O, Plouin P, Jambaque I. Predicting favourable outcomes in idiopathic West Syndrome. Epilepsia 1993; 34: 747–56PubMedCrossRefGoogle Scholar
  46. 46.
    Bachman DS. Use of valproic acid in the treatment of infantile spasms. Arch Neurol 1982; 39: 49–52PubMedCrossRefGoogle Scholar
  47. 47.
    Dreifuss F, Farwell J, Holmes G, et al. Infantile spasms: comparative trial of nitrazepam and corticotrophin. Arch Neurol 1986; 43: 1107–10PubMedCrossRefGoogle Scholar
  48. 48.
    Chiron C, Dulac O, Beaumont D, et al. Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol 1991; 6 Suppl. 2: S52–9Google Scholar
  49. 49.
    Snead Oc. Treatment of infantile spasms. Pediatr Neurol 1990; 6: 147–50PubMedCrossRefGoogle Scholar
  50. 50.
    Hrachovy RA, Frost JD Jr, Kellaway P, et al. Double-blind study of ACTH vs 3 prednisone therapy in infantile spasms. J Pediatr 1983; 103: 641–5PubMedCrossRefGoogle Scholar
  51. 51.
    Glaze DG, Hrachovy RA, Frost JD Jr, et al. Prospective study of outcome of infants with infantile spasms treated during controlled studies of ACTH and prednisone. J Pediatr 1988; 112: 389–96PubMedCrossRefGoogle Scholar
  52. 52.
    Aicardi J. The Lennox-Gastaut syndrome. Int Pediatr 1988; 3: 152–7Google Scholar
  53. 53.
    Gastaut H, Roger J, Soulayrol R, et al. Childhood epileptic encephalopathy with diffuse slow spike-waves (otherwise known as “petit mal variant” or Lennox syndrome). Epilepsia 1966; 7: 139–79CrossRefGoogle Scholar
  54. 54.
    Blume WT, David RB, Gomez MR. Generalized sharp and slow wave complexes. Associated clinical features and long term follow-up. Brain 1973; 96: 289–306PubMedCrossRefGoogle Scholar
  55. 55.
    Felbamate Study Group. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993; 328: 29–33CrossRefGoogle Scholar
  56. 56.
    Timmings PL, Richens A. Lamotrigine as an add-on drug in the management of Lennox-Gastaut syndrome. European Neuropsychopharm 1992; 32: 305–7Google Scholar
  57. 57.
    Foletti G, Schmidt M, Delisle MC, et al. An open study of effectiveness of lamotrigine in the treatment of secondary bilateral synchrony, unsatisfactorily controlled by conventional drugs [abstract]. J Neurol 1992; 239 Suppl.2: S71Google Scholar
  58. 58.
    Dulac O, Chiron C, Luna D, et al. Vigabatrin in childhood epilepsy. J Child Neurol 1991; 6 Suppl.2: S30–7Google Scholar
  59. 59.
    Porter RJ. The absence epilepsies. Epilepsia 1993; 34 Suppl.3: S42–8Google Scholar
  60. 60.
    Sato S, Dreifuss FE, Penry JK, et al. Long-term follow-up of absence seizures. Neurology 1983; 33: 1590–5PubMedCrossRefGoogle Scholar
  61. 61.
    Greenberg DA, Delgado-Escueta AY, Widelitz H, et al. Juvenile myoclonic epilepsy (JME) may be linked to the BF and HLA loci of human chromosome 6. Am J Med Genet 1988; 31: 185–92PubMedCrossRefGoogle Scholar
  62. 62.
    Wolf P. Juvenile myoclonic epilepsy. In: Roger J, Dravet C, Bureau M, et al., editors. Epileptic syndromes in infancy, childhood and adolescence. London: John Liggey Eurotext Ltd., 1985: 247–58Google Scholar
  63. 63.
    Janz D. Epilepsy with impUlsive-petit mal (juvenile myoclonic epilepsy). Acta Neurol Scand 1985; 72: 449–59PubMedCrossRefGoogle Scholar
  64. 64.
    Panayiotopoulos Cp. Benign childhood epilepsy with occipital paroxysms: a 15-year prospective study. Ann Neurol 1989; 26: 51–6PubMedCrossRefGoogle Scholar
  65. 65.
    Jeavons PM. Nosological problems of myoclonic epilepsies in childhood and adolescence. Dev Med Child Neurol 1977; 19: 3–8PubMedCrossRefGoogle Scholar
  66. 66.
    Penry JK, Dean JC, Riela AR. Juvenile myoclonic epilepsy: long-term response to therapy. Epilepsia 1989; 30 Suppl.4: S19–23CrossRefGoogle Scholar
  67. 67.
    Obeid T, Panayiotopoulos CP. Clonazepam in juvenile myoclonic epilepsy. Epilepsia 1989; 30: 603–6PubMedCrossRefGoogle Scholar
  68. 68.
    Resor SR, Resor LD. Chronic acetazolamide monotherapy in the treatment of juvenile myoclonic epilepsy. Neurology 1990; 40: 1677–81PubMedCrossRefGoogle Scholar
  69. 69.
    Appleton RE. The role of vigabatrin in the management of infantile epileptic syndromes. Neurology 1993; 43 Suppl.5: S21–3Google Scholar
  70. 70.
    Gibbs, Appleton RE, Rosenbloom L. Vigabatrin in intractable childhood epilepsy: a retrospective study. Pediatric Neurol 1992; 8: 338–40CrossRefGoogle Scholar
  71. 71.
    Branter S, Feucht M. Gamma-vinyl GAB A (vigabatrin) in Lennox-Gastaut syndrome—an open trial [abstract]. Seizure 1992; 1 Suppl.A: P705Google Scholar
  72. 72.
    Appleton RE, Hughes AP, Beime M, et al. Vigabatrin in the Landau- Kleffnersyndrome. Dev Med Child Neurol 1993; 35: 457–9PubMedGoogle Scholar
  73. 73.
    Pedersen B. Vigabatrin in the management of drug-resistant epilepsy in patients with tuberous sclerosis [abstract]. Epilepsia 1991; 32 Suppl. 1: 24Google Scholar
  74. 74.
    Dulac O, Withers RM, Yuen AWC. Add-on lamotrigine in pediatric patients with treatment resistant epilepsy [abstract]. Epilepsia 1991; 32 Suppl.1: 95Google Scholar
  75. 75.
    Sussman LD, Ritter FJ, Leppil IE, et al. Dramatic response to lamotrigine in two patients with neurological deficits secondary to frequent intractable seizures [abstract]. Epilepsia 1989; 31: 665Google Scholar
  76. 76.
    Canadian Clobazam Cooperative Group. Clobazam in treatment of refractory epilepsy: the Canadian experience. Aretrospective study. Epilepsia 1991; 32: 407–16CrossRefGoogle Scholar
  77. 77.
    Keene DL, Whiting S, Humphreys P. Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. Can J Neurol Sci 1990; 17: 317–9PubMedGoogle Scholar
  78. 78.
    Iinuma K, Handa I, Fueki N, et al. Effects of zonisamide (AD- 810) on refractory epilepsy in children: special reference to temporal lobe abnormalities. Curr Ther Res 1988; 43: 281–90Google Scholar
  79. 79.
    Sakamoto K, Kurokawa T, Tomita S, et al. Effects of zonisamide in children with epilepsy. CUff Ther Res 1988; 43: 378–83Google Scholar
  80. 80.
    Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 1990; 42: 223–86PubMedGoogle Scholar
  81. 81.
    Gilman IT. Intractable childhood epilepsy: issues in pharmacotherapy. J Epilepsy 1990; 3 Suppl.: 21–4Google Scholar
  82. 82.
    Eeg-Olofsson O, Nilsson HL, Tonnby B, et al. Diurnal variation in carbamazepine and carbamazepine 1O,1I-epoxide in plasma and saliva in children with epilepsy: a comparison between conventional and slow-release formulations. J Child Neurol 1990; 5: 159–65PubMedCrossRefGoogle Scholar
  83. 83.
    Ryan SW, Forsythe I, Hartley R, et al. Slow release carbamazepine in treatment of poorly controlled seizures. Arch Dis Child 1990; 65: 930–5PubMedCrossRefGoogle Scholar
  84. 84.
    Besunder JB, Reed MD, Blumer JL. Principles of drug biodisposition in the neonate: a critical evaluation of the pharmacokinetic- pharmacodynamic interface (Part I). Clin Pharmacokinet 1988; 14: 189–216PubMedCrossRefGoogle Scholar
  85. 85.
    Scheffner D, Konig St, Rautergerg-Ruland I, et al. Fatal liver failure in 16 children with valproate therapy. Epilepsia 1988; 29: 530–42PubMedCrossRefGoogle Scholar
  86. 86.
    Granneman G, Wang S, Kesterson J, et al. The hepatotoxicity of valproic acid and its metabolites in rats. II. Intermediary and valproic acid metabolism. Hepatology 1984; 4: 1153–8PubMedCrossRefGoogle Scholar
  87. 87.
    Shear NH, Spielberg SP. AnticonvulsljIlt hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest 1988; 82: 1826–32PubMedCrossRefGoogle Scholar
  88. 88.
    Elyas AA, Patsalos PN, Agbato OA, et al. Factors influencing simultaneous concentrations of total and free carbamazepine and carbamazepine-IO, ll-epoxide in serum of children with epilepsy. Ther Drug Monit 1986; 8: 288–92PubMedCrossRefGoogle Scholar
  89. 89.
    Doig M, Clare R. Use of thermospray liquid chromatographymass spectrometry to aid in the identification of urinary metabolites of a novel antiepileptic drug, lamotrigine. J Chromatogr 1991; 554: 181–9PubMedCrossRefGoogle Scholar
  90. 90.
    Mikati MA, Schachter SC, Schomer DL, et al. Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. Clin Neuropharmacol 1989; 12: 312–21PubMedCrossRefGoogle Scholar
  91. 91.
    Segelman FH, Kelton E, Terzi RM, et al. The comparative potency of phenobarbital and five 1,3-propanediol dicarbamaztes for hepatic cytochrome P450 induction in rats. Res Commun Chern Pathol Pharmacol 1985; 48: 467–70Google Scholar
  92. 92.
    Graves NM. Felbamate. Ann Pharmacother 1993; 27: 1073–81PubMedGoogle Scholar
  93. 93.
    Hauser WA, Hesdorffer DC, editors. Prognosis. In: Epilepsy: frequency, causes and consequences. New York, New York: Demos Publications, 1990: 327–47Google Scholar
  94. 94.
    Shinnar S, Vining EPG, Mellits ED. Discontinuing antiepileptic medications in children with epilepsy after two years without seizures. N Eng J Med 1985; 313: 976–80CrossRefGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Jamie T. Gilman
    • 1
    • 2
  • Michael Duchowny
    • 1
  1. 1.Department of Neuroscience and Comprehensive Epilepsy CenterMiami Children’s HospitalMiamiUSA
  2. 2.Division of Clinical Pharmacology and Pharmacokinetics LaboratoryMiami Children’s HospitalMiamiUSA

Personalised recommendations